Drug research

Plozasiran Injection

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as ARO-APOC3

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Long-Term Safety and Efficacy of Plozasiran in Adults With HypertriglyceridemiaNCT06822790	Arrowhead Pharmaceuticals	Phase 3	Recruiting	2028-07Estimated
Study of Plozasiran (ARO-APOC3) in Adults With Severe HypertriglyceridemiaNCT06347003	Arrowhead Pharmaceuticals	Phase 3	Active not recruiting	2026-06-12Actual
Phase 3 Study of Plozasiran in Adults With HypertriglyceridemiaNCT06347133	Arrowhead Pharmaceuticals	Phase 3	Completed	2026-06-01Actual
Study of Plozasiran in Adults With Severe HypertriglyceridemiaNCT06347016	Arrowhead Pharmaceuticals	Phase 3	Active not recruiting	2026-06-17Actual

Arrowhead PharmaceuticalsRecruitingPrimary completion: 2028-07 · Estimated

Trial details

Arrowhead PharmaceuticalsActive not recruitingPrimary completion: 2026-06-12 · Actual

Trial details

Arrowhead PharmaceuticalsCompletedPrimary completion: 2026-06-01 · Actual

Trial details

Arrowhead PharmaceuticalsActive not recruitingPrimary completion: 2026-06-17 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.